Lyell Immunopharma, Inc. is a late-stage clinical cell therapy company developing proprietary autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. The company focuses on hematologic malignancies and solid tumors, with a lead product candidate, rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. Lyell is conducting pivotal clinical trials, including PiNACLE and PiNACLE-H2H, to evaluate ronde-cel in the third-line and second-line settings. Additionally, the company is advancing LYL273, an autologous guanylyl cyclase C-targeted CAR T-cell product candidate for advanced metastatic colorectal cancer, acquired from Innovative Cellular Therapeutics. Lyell operates the LyFE Manufacturing Center to produce these cell therapy products, supporting its clinical trials and potential commercial launches.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lyell.com
Sector Healthcare IR page ir.lyell.com
Tags
car-t-cell-therapy, hematologic-malignancies, solid-tumors, large-b-cell-lymphoma, metastatic-colorectal-cancer, cell-therapy-manufacturing, autologous-cell-therapy, oncology, rondecabtagene autoleucel, ronde-cel, LYL314, LYL273, GCC19CART, LyFE Manufacturing Center, PiNACLE, PiNACLE-H2H, Innovative Cellular Therapeutics Holdings Limited, Innovative Cellular Therapeutics Inc.
Press page —

Metrics

Valuation  
Market cap $ 391.582M
Market cap (USD) $ 391.582M
P/E -1.27
PEG —
P/BV 2.03
P/S —
P/OCF -2.81
P/FCF -2.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -87.0%
ROI -119.4%
ROIC -87.9%
Profit margin -762,355.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 36K 61K 130K 84.683M 10.65M 7.756M
Net profit -274.448M -342.994M -234.632M -183.118M -250.219M -204.472M
Free cash flow -150.804M -162.858M -166.38M -193.831M -191.753M -212.355M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 30.78 — 2.28 6.4 17 —
Price performance 12m — — -0.64 -0.62 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 51M 67.8M 67.7M 63.2M 59M 51M
Cash and deposits (USD) 130M 98.5M 140M 294M 124M 146M 106M 60.2M
Right-of-use assets (USD) — — 47M 46.5M 43.2M 39.7M 24.7M 18.9M
Cash flow detail
Operating cash flow (USD) — 39.5M -161M -126M -170M -164M -162M -150M
Purchases of property, plant and equipment (USD) — -16M -51.5M -65.5M -24.3M -2.69M -464,000 -780,000
Change in payables (cash effect) (USD) — 1.71M -278,000 91,000 667,000 1.46M -3.23M -2.34M
Share buybacks (cash effect) (USD) — -185,000 -11.8M 0.00 0.00 — — —
Share-based compensation (USD) — 15.7M 33.3M 62.2M 81.9M 47.1M 33.1M 41.8M
Free cash flow (OCF - PPE - intangibles) (USD) — 23.4M -212M -192M -194M -166M -163M -151M
Income detail
Research and development expense (USD) — 63.6M 182M 139M 159M 183M 172M 159M
↳ 5y CAGR +22.0% -2.7%
Total comprehensive income (USD) — -129M -205M -252M -189M -227M -343M -274M
Comprehensive income to owners (USD) — -129M -205M -252M -189M -227M -343M -274M
Reported Mar 29, 2022 Mar 29, 2022 Mar 29, 2022 Mar 29, 2022 Feb 28, 2023 Feb 28, 2024 Mar 11, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at ASH 2026.

•The overall response rate was 91% and the complete response rate was 77% among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial. The median duration of complete response and median progression-free survival were not reached, with an estimated continued complete response rate of 92% at six months and 75% at 12 months. No Grade ≥ 3 CRS was observed and Grade ≥ 3 ICANS was reported in 9% of patients.

•PiNACLE pivotal data disclosure is on track for mid-2027, with BLA submission expected to follow in the second half of 2027.

•Completed technology transfer of LYL273 to the LyFE Manufacturing Center™ following FDA review of improved manufacturing process and updated analytical methods; additional clinical data and End-of-Phase 1 meeting with FDA expected in 2027.

•Announced private placement financing of $80.0 million with participation from a high-quality syndicate of existing and new investors.

On November 3, 2026, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors an aggregate of 7,428,040 shares (“Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $10.77 per Share, in a private placement transaction (the “Private Placement”). The closing of the Private Placement is scheduled to occur on or about November 4, 2026 (the “Closing”), subject to the satisfaction of customary closing conditions. The total gross proceeds from the Private Placement, before expenses, are expected to be approximately $80.0 million. The Company is relying upon on the exemption from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof. Each of the Investors provided representations appropriate for a private placement of securities. Restrictive legends will be affixed to the Shares.

September 14, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.

A live webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the webcast will be available on the Company's website following the event.

About Lyell Immunopharma, Inc.

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s proprietary LyFE Manufacturing Center™ has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Prompts

Lyell Immunopharma, Inc. (ticker LYEL), listed in United States.

ETFs Holding Lyell Immunopharma, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 23,990 $ 351.454K Nov 16, 2026
DXUV 0.00% 1,896 $ 29.653K Nov 12, 2026
DFAS 0.00% 7,790 $ 121.836K Nov 12, 2026
DCOR 0.00% 1,961 $ 30.67K Nov 12, 2026
AVUS 0.00% 346 $ 5,068.90 Nov 16, 2026